Press
Releases
Press Releases
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 8, 2021-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an
Jul 08, 2021
AVROBIO to Present at the JMP Securities Life Sciences Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 10, 2021-- AVROBIO, Inc. (Nasdaq:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Geoff MacKay , president and CEO of AVROBIO , will present at the JMP Securities Life
Jun 10, 2021
AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 4, 2021-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted a non-statutory stock option for the purchase of up to an
Jun 04, 2021
AVROBIO Reports First Quarter 2021 Financial Results and Provides Business Update
Held meeting with the U.S. Food and Drug Administration (FDA) to discuss the regulatory path for AVR-RD-01 for Fabry disease Dosing completion in ongoing FAB-GT Phase 2 trial reaches 50%, with three additional patients dosed in three months CAMBRIDGE, Mass.
May 13, 2021
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 6, 2021-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an
May 06, 2021
AVROBIO Provides Regulatory Update on Investigational AVR-RD-01 for Fabry Disease
Anticipates initiating registration trial with kidney biopsy endpoint in mid-2022 to support potential full approval of AVR-RD-01 as first-line therapy, subject to FDA discussion and agreement Two additional patients dosed in last two months in ongoing FAB-GT Phase 2 trial; plan to enroll a total
May 03, 2021
AVROBIO to Present Clinical and Preclinical Data at the ASGCT 24th Annual Meeting
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 27, 2021-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that two oral presentations and two posters featuring data from its pipeline of
Apr 27, 2021
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 6, 2021-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an
Apr 06, 2021
AVROBIO Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Business Update
100% kidney substrate reduction at 12 months post-gene therapy in the first patient dosed with the plato ® gene therapy platform in FAB-GT 1 trial for Fabry disease One new patient dosed and three new patients enrolled in Fabry disease clinical trial since January 2021 Orphan drug designation
Mar 18, 2021
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 5, 2021-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an
Mar 05, 2021
Displaying 1 - 10 of 19